Crohn's Disease Market Expected To Witness Sublimation With A CAGR Of 3%
Posted by Merin John on July 13th, 2021
The forecast period will witness a shift of notion about healthcare from just being “sick care” to “health and wellness”. The Crohn’s Disease Treatment Market entails the integration of this shift into the design of delivery locations/channels and service offerings by the key market participants. This could include at-home prescription delivery, virtual care, self-service application for behavior modification, and decision support.
The Crohn’s & Colitis Foundation of America (CCFA) stated that over 1 Million Americans were diagnosed with Crohn’s & ulcerative colitis disorders, with most of them aged above 30. Growing occurrence of Crohn’s disease has triggered a robust demand for its therapeutics. A survey conducted by the US Center for Disease Control (CDC) has revealed that the incidence rate of Crohn’s disease in the country is 3.1 to 14.6 new cases per 100,000 population annually.
The disease is highly prevalent in developed countries, especially in individuals who smoke. According to a study conducted by Persistence Market Research (PMR), demand for anti-inflammatory drugs and biologics for treating Crohn’s disease will gain traction in the near future. PMR forecasts that the global market for Crohn’s disease is set to reach US$ 4,474.8 Million by 2024-end, growing at a CAGR of 3% during the assessment period.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/9665
Increasing demand for biologics for treating bowel disorders such as ulcerative collates and Crohn’s disease is propelling the overall growth of Crohn’s disease market. Moreover, drug manufacturers are actively focusing on advanced products having higher efficiency. The growing patient population is an additional factor expected to influence the market growth between 2016 and 2024.
Therefore, higher utilization and preference for biologics and anti-inflammatory drug therapies coupled with the surging popularity of biosimilars is expected to play an important role in shaping the market for the future.
The high cost of treatment will remain as a major impediment for the market. Further, the patient expiry of blockbuster drugs and lack of early diagnosis particularly in third world countries are some of the other hindrances that are likely to inhibit the market growth during the forecast period.
Higher preference for symptomatic therapeutic and drugs over surgeries, better treatment management of inflammatory bowel diseases, the arrival of enhanced drugs in the market owing to healthier investments in R&D programs are some of the key trends governing the market.
While biologics will continue to remain the most preferred drug type amongst both healthcare professionals and patients, the demand for anti-inflammatory drugs will also witness a rampant acceleration during the forecast period. Based on drug type, the anti-inflammatory drug segment is projected to reach a market valuation of US$ 1,095.9 Million by end of the assessment period.
Based on distribution channel, the hospital pharmacies will continue to be the leading segment of the market over the forecast period. Whereas, the retail pharmacies segment is projected to exhibit the highest growth, reaching a market valuation of US$ 1,470.2 Million by 2024.
PMR’s findings based on regional assessment suggest that the Crohn’s disease market in North America will continue to lead the pack during the forecast period. The region’s market is expected to value US$ 3,149.8 Million over 2014. However, Asia-Pacific is expected to witness the highest CAGR over the forecast period. The APAC market is projected to create an absolute $ opportunity of US$ 13.2 Million in 2017 over 2016.
Like it? Share it!
About the AuthorMerin John
Joined: December 11th, 2020
Articles Posted: 262
More by this author